1. A method of treating HER2-positive cancer, comprising administering a combination of paclitaxel and T-DM1 human patient with HER2-positive cancer, said paclitaxel is administered in a dose of 65 mg / mi to 80 mg / mezhenedelno and T-DM1 administered at a dose of 2 , 4-3,6 mg / kg every three nedeli.2. The method of claim. 1, characterized in that the T-DM1 administered at a dose selected from 2.4, 3.0 and 3.6 mg / kg every three nedeli.3. A method according to claim. 2, wherein the paclitaxel is administered in a dose of 80 mg / mezhenedelno and T-DM1 administered at a dose selected from 2.4, 3.0 and 3.6 mg / kg every three nedeli.4. A method according to claim. 2, wherein the paclitaxel is administered in a dose of 65 mg / mezhenedelno and T-DM1 administered at a dose selected from 2.4, 3.0 and 3.6 mg / kg every three nedeli.5. A method according to claim. 3, characterized in that it further comprises administering pertuzumab 420 mg three times a nedeli.6. The method of claim. 5, characterized in that the initial loading dose is administered in 840 mg of pertuzumab, and then to 420 mg administered every three nedeli.7 pertuzumab. A method according to claim. 4, characterized in that it further comprises administering pertuzumab 420 mg three times a nedeli.8. A method according to claim. 7, characterized in that the initial loading dose is administered in 840 mg of pertuzumab, and then to 420 mg administered every three nedeli.9 pertuzumab. A method according to any one of claims. 1-8, wherein the HER2-positive cancer is a HER2-positive breast cancer zhelezy.10. A method according to claim. 9, characterized in that the HER2-pozitivnyyrak breast is metastaticheskim.11. A method according to any one of claims. 1-8, wherein the HER2-positive cancer expressing HER2 at 3 + .12. A method of treating HER2-positive cancer, comprising administering a combination of paclitaxel and T-DM1 human patient with HER2-positive cancer, said paclitaxel is administered in a dose of1.
